Genetics of cisplatin ototoxicity: Confirming the unexplained?

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 2, 2013, Pages 198-200

  Boddy, A V ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CARBOPLATIN; CISPLATIN; CYTOCHROME P450 2D6; IRINOTECAN; MERCAPTOPURINE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; SODIUM THIOSULFATE; TAMOXIFEN; VINCRISTINE;

ALTERNATIVE MEDICINE; CHILDHOOD CANCER; CRANIOSPINAL IRRADIATION; DNA METHYLATION; DNA REPAIR; DRUG ACTIVATION; DRUG INACTIVATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GENETIC VARIABILITY; GENOTYPE; HEARING IMPAIRMENT; HUMAN; LYMPHOBLASTOID CELL LINE; OTOTOXICITY; OUTCOME ASSESSMENT; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; RETINOBLASTOMA; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; ANTINEOPLASTIC AGENTS; CATECHOL O-METHYLTRANSFERASE; CISPLATIN; FEMALE; HEARING LOSS; HUMANS; MALE; METHYLTRANSFERASES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS;

EID: 84880731033     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.116     Document Type: Review

References (11)

1. Pussegoda, K. et al. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin. Pharmacol. Ther. 94, 243-251 (2013).
2. Ross, C.J. et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 41, 1345-1349 (2009).
3. Qaddoumi, I. et al. Carboplatin-associated ototoxicity in children with retinoblastoma. J. Clin. Oncol. 30, 1034-1041 (2012).
4. Picton, S.V., Keeble, J., Holden, V., Errington, J., Boddy, A.V. & Veal, G.J. Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma. Cancer Chemother. Pharmacol. 63, 749-752 (2009).
5. Yang, J.J. et al. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin. Pharmacol. Ther. 94, 252-259 (2013).
6. Ross, C.J. et al. Corrigendum: genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 45, 578 (2013).
7. Schroth, W. et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25, 5187-5193 (2007). (Pubitemid 350232249)
8. Barginear, M.F. et al. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin. Pharmacol. Ther. 90, 605-611 (2011).
9. Kelly, C.M. & Pritchard, K.I. CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned. J. Natl Cancer Inst. 104, 427-428 (2012).
10. Muldoon, L.L. et al. Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin. Cancer Res. 6, 209-315 (2000).
11. Harned, T.M. et al. Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity. Clin. Cancer Res. 14, 533-540 (2008). (Pubitemid 351226123)